Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $6.4 million.

  • Mereo BioPharma's Total Non-Current Liabilities fell 5812.79% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 5812.79%. This contributed to the annual value of $14.6 million for FY2024, which is 393.47% down from last year.
  • Latest data reveals that Mereo BioPharma reported Total Non-Current Liabilities of $6.4 million as of Q3 2025, which was down 5812.79% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Total Non-Current Liabilities peaked at $76.0 million during Q2 2021, and registered a low of $4.1 million during Q2 2022.
  • Over the past 5 years, Mereo BioPharma's median Total Non-Current Liabilities value was $14.9 million (recorded in 2024), while the average stood at $19.7 million.
  • Per our database at Business Quant, Mereo BioPharma's Total Non-Current Liabilities tumbled by 312.89% in 2021 and then tumbled by 9462.37% in 2022.
  • Quarter analysis of 5 years shows Mereo BioPharma's Total Non-Current Liabilities stood at $34.9 million in 2021, then fell by 27.92% to $25.1 million in 2022, then crashed by 39.55% to $15.2 million in 2023, then decreased by 3.93% to $14.6 million in 2024, then plummeted by 56.49% to $6.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $6.4 million for Q3 2025, versus $7.9 million for Q2 2025 and $7.8 million for Q1 2025.